DiaceuticsFRA:7DC +1.23%90 PB Ratio is 3.00 as of Jul. 02, 2026, which is 14% above its 10-year median of 2.64. GuruFocus rates FRA:7DC with a GF Score™ of 90/100 and a GF Value™ of €2.13 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 609 Healthcare Providers & Services companies, Diaceutics ranks worse than 68.31% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-02), Diaceutics's share price is €1.64. Diaceutics's Book Value per Share for the quarter that ended in Dec. 2025 was €0.55. Hence, Diaceutics's PB Ratio of today is 3.00.
The historical rank and industry rank for Diaceutics's PB Ratio or its related term are showing as below:
FRA:7DC'
s PB Ratio Range Over the Past 10 Years
Min: 1.53 Med: 2.64 Max: 27.24
Current: 3.09
During the past 10 years, Diaceutics's highest PB Ratio was 27.24. The lowest was 1.53. And the median was 2.64.
FRA:7DC's PB Ratio is ranked worse than 68.31% of 609
companies
in the Healthcare Providers & Services industry
Industry Median: 1.96
vs FRA:7DC: 3.09
During the past 12 months, Diaceutics's average Book Value Per Share Growth Rate was 1.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -1.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -0.40% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Diaceutics was 168.10% per year. The lowest was -1.80% per year. And the median was 20.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Diaceutics PB Ratio Related Terms
Diaceutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Diaceutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Diaceutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Diaceutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Diaceutics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Diaceutics (FRA:7DC) has a PB Ratio of 3.00 as of Jul. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Diaceutics and its competitors. This is 14% above median its historical median of 2.64. Over the past decade, Diaceutics' PB Ratio has ranged from 1.53 to 27.24. According to the industry distribution chart, Diaceutics ranks #416 out of 609 companies in the Healthcare Providers & Services industry, placing it in the top 68.3%.
Is Diaceutics' PB Ratio too high?
Diaceutics' current PB Ratio of 3.00 is 14% above median its 10-year median of 2.64. Over the past 10 years, this metric has ranged from a low of 1.53 to a high of 27.24. The Healthcare Providers & Services industry median PB Ratio is 1.96. Diaceutics' value of 3.00 is 53.1% above this industry median. Based on the distribution chart, Diaceutics ranks #416 out of 609 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Diaceutics has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' PB Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #416 out of 609 companies for PB Ratio. This places Diaceutics in the lower half of its industry. The industry median PB Ratio is 1.96. Diaceutics' value of 3.00 is 53.1% above this benchmark. Historically, Diaceutics' own PB Ratio has ranged from 1.53 to 27.24 over the past decade. While the company's 10-year median is 2.64 vs. the industry median of 1.96, Diaceutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 1.96, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current PB Ratio of 3.00 is 53.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Diaceutics and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current PB Ratio is 3.00, which is 14% above median its own 10-year median of 2.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (FRA:7DC) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.13, compared to a current price of €1.64 — trading 23% below its estimated fair value. The current PB Ratio is 3.00, which is 14% above median its 10-year median of 2.64 and 53.1% above the Healthcare Providers & Services industry median of 1.96. Diaceutics' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Diaceutics (FRA:7DC), the current PB Ratio is 3.00 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (FRA:7DC) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of €1.64 is trading 23% below its estimated GF Value™ of €2.13.
GuruFocus considers Diaceutics to be Modestly Undervalued.
Key valuation signals for FRA:7DC:
PB Ratio: 3.00 (14% above median its 10-year median of 2.64)
GF Value™: €2.13 vs. price of €1.64 (23% below fair value)
Industry Position: 53.1% above the Healthcare Providers & Services median (#416 of 609)
No single metric tells the full story. See the FRA:7DC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
90GF Score
Get the complete analysis for FRA:7DC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7DC has been successfully added to your 
